Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes

MANCHESTER, NH--(Marketwired - Sep 16, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its lead drug candidate, as a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes (EASD 2014), to be held September 15-19 in Vienna, Austria.

The poster, titled "Insight into the molecular mechanism of action of BTI-320, a non-systemic novel drug to control serum glucose levels in individuals with diabetes," was written by a team of researchers led by Kevin H. Mayo, Ph.D., a professor in the Department of Biochemistry, Molecular Biology and Biophysics at the University of Minnesota, Minneapolis. Dr. Mayo led the pre-clinical study that recently discovered molecular mechanism of action of BTI-320. The poster's co-authors include David Platt, Ph.D., CEO of Boston Therapeutics, and Benjamin Rivnay, Ph.D., Chief Scientist.

The team investigated whether two substances in BTI-320 (galactomannans GM-a and GM-b) interact directly with hydrolyzing enzymes that break down carbohydrates like starch, sucrose or maltose into glucose, and can function to attenuate the rate of glucose release from digested foods. The researchers concluded that GM-a acts as a competitive inhibitor of maltase and sucrase, and possibly of a-amylase, and is the more active ingredient in BTI-320.

Dr. Platt said, "Our findings provide insight into how BTI-320 might function in vivo and support the potential viability of BTI-320 as an alternative to acarbose therapy for glycemic control in patients with diabetes. We are proud to be able to present this research at EASD 2014 and will continue to report additional findings as we obtain them."

About BTI-320

BTI-320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose in Type 2 diabetic patients. BTI-320 is a proprietary polysaccharide to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a non-systemic therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. The company also developed and currently markets SUGARDOWN^®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at www.bostonti.com.

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.